Journal
PHARMACEUTICALS
Volume 13, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/ph13080188
Keywords
SARS-CoV-2; coronavirus; COVID-19; remdesivir; antiviral; vaccine
Categories
Funding
- St. Baldrick Foundation Jack's Pack -We Still Have His Back-a St. Baldrick's Hero Fund
- Charles H. Hood Foundation Child Health Research Award
- NIH R01 grant [1R01CA241194-01A1, 1R01HL147028-01A1]
Ask authors/readers for more resources
The novel SARS-CoV-2 virus has quickly spread worldwide, bringing the whole world as well as the economy to a standstill. As the world is struggling to minimize the transmission of this devastating disease, several strategies are being actively deployed to develop therapeutic interventions. Pharmaceutical companies and academic researchers are relentlessly working to investigate experimental, repurposed or FDA-approved drugs on a compassionate basis and novel biologics for SARS-CoV-2 prophylaxis and treatment. Presently, a tremendous surge of COVID-19 clinical trials are advancing through different stages. Among currently registered clinical efforts, similar to 86% are centered on testing small molecules or antibodies either alone or in combination with immunomodulators. The rest similar to 14% of clinical efforts are aimed at evaluating vaccines and convalescent plasma-based therapies to mitigate the disease's symptoms. This review provides a comprehensive overview of current therapeutic modalities being evaluated against SARS-CoV-2 virus in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available